Evidence map›Paper›PMID 12857780›Full record

ReviewClinical microbiology reviews2003

Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes.

Mairi C Noverr, John R Erb-Downward, Gary B Huffnagle

Open access · greenAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 237 citations in OpenAlex.

  1. Review
  2. Article
  3. The role ofMicrobiology spectrum · 2026
    Article
  4. Pathogens (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Pioneering Metabolomic Studies onMolecules (Basel, Switzerland) · 2023
    Article
  15. Article
  16. The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mairi C NoverrDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0642, USA.
John R Erb-Downward
Gary B Huffnagle
Pulmonary and Critical Care Associates · USUniversity of Michigan–Ann Arbor · US

Funding

Molecular Mechanisms of Microbial Pathogenesis Training ProgramT32AI007528 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARRUTHERS, VERNON BRUCE · 1998 to 2024
$6.8M
MODULATION OF TH1/TH2 RESPONSES BY INNATE IMMUNITYR01HL065912 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUFFNAGLE, GARY B. · 2000 to 2004
$1.5M
CHEMOKINE RECEPTORS IN IMMUNITY TO C NEOFORMANSR01HL063670 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUFFNAGLE, GARY B. · 1999 to 2003
$1.1M
NHLBI NIH HHS R01 HL065912NHLBI NIH HHS R01-HL63670NHLBI NIH HHS R01-HL65912NIAID NIH HHS T32 AI007528NIAID NIH HHS T32AI07528Wellcome Trust
6 · The paper itself

Abstract

Oxylipins are oxygenated metabolites of fatty acids. Eicosanoids are a subset of oxylipins and include the prostaglandins and leukotrienes, which are potent regulators of host immune responses. Host cells are one source of eicosanoids and oxylipins during infection; however, another potential source of eicosanoids is the pathogen itself. A broad range of pathogenic fungi, protozoa, and helminths produce eicosanoids and other oxylipins by novel synthesis pathways. Why do these organisms produce oxylipins? Accumulating data suggest that phase change and differentiation in these organisms are controlled by oxylipins, including prostaglandins and lipoxygenase products. The precise role of pathogen-derived eicosanoids in pathogenesis remains to be determined, but the potential link between pathogen eicosanoids and the development of TH2 responses in the host is intriguing. Mammalian prostaglandins and leukotrienes have been studied extensively, and these molecules can modulate Th1 versus Th2 immune responses, chemokine production, phagocytosis, lymphocyte proliferation, and leukocyte chemotaxis. Thus, eicosanoids and oxylipins (host or microbe) may be mediators of a direct host-pathogen "cross-talk" that promotes chronic infection and hypersensitivity disease, common features of infection by eukaryotic pathogens.

Indexed as

AnimalsEicosanoidsEukaryotaFungiHelminthiasisHelminthsMycosesProtozoan InfectionsEicosanoids

Identifiers

PMID12857780
PMCPMC164223
OpenAlexW2103684899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.